Furthermore, a multicenter cohort study of 74 participants revealed a 91% detection rate of JAK2 mutation in MPNs-associated CVST, significantly higher than in the general MPN population [24]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.